Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Inhibition of Itk potentially constitutes a novel, nonsteroidal treatment for asthma and other T-cell mediated diseases. In-house kinase cross-screening resulted in the identification of an aminopyrazole-based series of Itk inhibitors. Initial work on this series highlighted selectivity issues with several other kinases, particularly AurA and AurB. A template-hopping strategy was used to identify a series of aminobenzothiazole Itk inhibitors, which utilized an inherently more selective hinge binding motif. Crystallography and modeling were used to rationalize the observed selectivity. Initial exploration of the SAR around this series identified potent Itk inhibitors in both enzyme and cellular assays.

[1]  David R. Anderson,et al.  Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay. , 2012, Journal of medicinal chemistry.

[2]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[3]  A. August,et al.  Regulation of T-cell Responses and Disease by Tec Kinase Itk , 2012, International reviews of immunology.

[4]  F. Giles,et al.  Targeting aurora kinases in cancer treatment. , 2011, Current drug targets.

[5]  Paul Bamborough,et al.  Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.

[6]  J. Grasis,et al.  Itk: The Rheostat of the T Cell Response , 2011, Journal of signal transduction.

[7]  A. Tanner,et al.  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. , 2011, Journal of medicinal chemistry.

[8]  J. Woska,et al.  5-Aminomethylbenzimidazoles as potent ITK antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[9]  Mohane Selvaraj Coumar,et al.  Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. , 2009, Journal of medicinal chemistry.

[10]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[11]  A. Doweyko,et al.  Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[12]  Daniel A. Erlanson,et al.  Fragment‐Based Drug Discovery. , 2004 .

[13]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[14]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[15]  Duncan E McRee,et al.  Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. , 2002, Structure.

[16]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[17]  H. Lo Itk inhibitors : a patent review , 2010 .

[18]  E. Bush,et al.  Data normalization before statistical analysis: keeping the horse before the cart. , 1988, Trends in pharmacological sciences.